We are live on
!
Find out more
TC
TFS Capital Portfolio holdings
AUM
$255M
1-Year Est. Return
32.31%
This Fund
S&P 500
This Quarter
Est. Return
-0.66%
1 Year Est. Return
+32.31%
3 Year Est. Return
+53.79%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$694M
AUM Growth
-$235M
(-25%)
Cap. Flow
-$209M
Cap. Flow
% of AUM
-30.05%
Top 10 Holdings %
Top 10 Hldgs %
4.41%
Holding
1,236
New
502
Increased
176
Reduced
298
Closed
257
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$2.36M |
| 2 |
Collegium Pharmaceutical
COLL
|
+$2.32M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$2.29M |
| 4 |
HSII
Heidrick & Struggles
HSII
|
+$2.25M |
| 5 |
HTCH
HUTCHINSON TECHNOLOGY INC
HTCH
|
+$2.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Emergent Biosolutions
EBS
|
+$5.99M |
| 2 |
Commercial Metals
CMC
|
+$5.95M |
| 3 |
Benchmark Electronics
BHE
|
+$5.84M |
| 4 |
Upbound Group
UPBD
|
+$5.71M |
| 5 |
FreightCar America
RAIL
|
+$5.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.04% |
| 2 | Industrials | 15.17% |
| 3 | Technology | 12.86% |
| 4 | Consumer Discretionary | 12.11% |
| 5 | Financials | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Encompass Health
EHC
$11.3B
| $347K | 0.05% |
+11,576
| New | +$320K |
|
|
NWY
602
DELISTED
New York & Co Inc
NWY
| $347K | 0.05% |
+87,621
| New | +$217K |
|
|
CCRN
603
DELISTED
Cross Country Healthcare
CCRN
| $345K | 0.05% |
29,705
-126,291
| -81% | -$1.6M |
|
|
FNSR
604
DELISTED
Finisar Corp
FNSR
| $345K | 0.05% |
18,932
-69,856
| -79% | -$1M |
|
|
NATL
605
DELISTED
National Interstate Corporation
NATL
| $344K | 0.05% |
+11,486
| New | +$297K |
|
606
Exponent
EXPO
$3.04B
| $342K | 0.05% |
+13,420
| New | +$324K |
|
|
SAVE
607
DELISTED
Spirit Airlines, Inc.
SAVE
| $340K | 0.05% |
+7,087
| New | +$317K |
|
|
BGFV
608
DELISTED
Big 5 Sporting Goods
BGFV
| $337K | 0.05% |
30,318
-76,419
| -72% | -$894K |
|
|
WEB
609
DELISTED
Web.com Group, Inc.
WEB
| $337K | 0.05% |
17,007
-206,441
| -92% | -$3.78M |
|
610
Genworth Financial
GNW
$3.79B
| $336K | 0.05% |
+123,239
| New | +$312K |
|
611
El Pollo Loco
LOCO
$493M
| $336K | 0.05% |
+25,180
| New | +$317K |
|
|
GBL
612
DELISTED
GAMCO Investors, Inc.
GBL
| $332K | 0.05% |
8,964
-3,057
| -25% | -$99.7K |
|
|
ACHN
613
DELISTED
Achillion Pharmaceuticals
ACHN
| $332K | 0.05% |
42,993
-257,123
| -86% | -$1.88M |
|
614
Frontline
FRO
$8.59B
| $329K | 0.05% |
+39,305
| New | +$380K |
|
|
POWR
615
DELISTED
POWERSECURE INTL INC COM STK (DE)
POWR
| $329K | 0.05% |
17,597
-139,338
| -89% | -$1.98M |
|
616
John Wiley & Sons Class A
WLY
$2.59B
| $328K | 0.05% |
+6,701
| New | +$293K |
|
617
VSE Corp
VSEC
$5.64B
| $326K | 0.05% |
+9,604
| New | +$291K |
|
618
GameStop
GME
$9.66B
| $325K | 0.05% |
+41,032
| New | +$295K |
|
|
CIO
619
DELISTED
City Office REIT
CIO
| $324K | 0.05% |
+28,442
| New | +$337K |
|
620
Molina Healthcare
MOH
$10.4B
| $323K | 0.05% |
+5,014
| New | +$298K |
|
621
Silgan Holdings
SLGN
$4.92B
| $319K | 0.05% |
+12,004
| New | +$312K |
|
622
Synaptics
SYNA
$4.55B
| $319K | 0.05% |
+4,005
| New | +$304K |
|
|
SMM
623
DELISTED
Salient Midstream & MLP Fund
SMM
| $318K | 0.05% |
+39,799
| New | +$297K |
|
624
Astronics
ATRO
$3.47B
| $317K | 0.05% |
+13,172
| New | +$279K |
|
625
World Kinect Corp
WKC
$2.04B
| $317K | 0.05% |
+6,529
| New | +$280K |
|
Similar funds
KC
IPC
ECPI
FRM
WFG
IFB
KL
RP
TFS Capital's Q1 2016 Portfolio in Review
As of Q1 2016, TFS Capital held 1,236 positions worth $694M, down 25% from $929M the previous quarter. Its ten largest holdings account for 4.4% of the portfolio.
TFS Capital withdrew a net $209M in Q1 2016, closing 257 positions and reducing 298 holdings. Its most notable exit was Benchmark Electronics, an estimated $5.84M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 22% a quarter earlier, followed by Industrials and Technology.
Against the trend, TFS Capital opened a new position in Collegium Pharmaceutical worth $2.31M.
- TFS Capital's largest Q1 2016 buy was Collegium Pharmaceutical: 127,568 shares worth $2.31M.
- TFS Capital added most to Infinity Pharmaceuticals, Inc. in Q1 2016, an estimated $2.36M increase.
- TFS Capital's biggest Q1 2016 reduction was Emergent Biosolutions, cutting an estimated $5.99M.
- TFS Capital fully exited Benchmark Electronics in Q1 2016, selling an estimated $5.84M.
- TFS Capital's ten largest holdings make up 4.4% of its $694M portfolio in Q1 2016.
- TFS Capital opened 502 new positions and closed 257 in Q1 2016.
- TFS Capital's portfolio value fell 25% quarter-over-quarter to $694M.
Based on TFS Capital's 13F filing for Q1 2016, filed 10 May 2016.